Clinical success with recombinant TRAIL or an agonistic DR5 antibody has not been demonstrated although the induction of apoptosis with these agents has emerged as an attractive cancer therapeutic strategy17, 33, 34. This evidence concerns the gene TNFSF10 and cancer.